Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8522232 | 0.81 | CYP19A1 (0.50) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL1614645 | 0.81 | CYP3A4 (0.47) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL17963323 | 0.78 | CYP3A4 (0.46) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL19627972 | 0.76 | CYP19A1 (0.57) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL29138449 | 0.76 | CYP19A1 (0.50) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL30048933 | 0.76 | CYP19A1 (0.50) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL11628920 | 0.74 | CYP19A1 (0.64) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL18133808 | 0.73 | TSHR (0.43) | CYP3A4CYP1A2CYP2C9CYP2C19KCNH2 | |
| SCHEMBL1614101 | 0.73 | CYP19A1 (0.43) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 | |
| SCHEMBL24371727 | 0.72 | CYP19A1 (0.53) | CYP19A1CYP3A4CYP3A5KCNA5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | CYP19A1 179/4885CYP3A4 801/4885CYP3A5 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.